Last reviewed · How we verify
Ketoconazole 200 mg
At a glance
| Generic name | Ketoconazole 200 mg |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- fatigue
- Musculoskeletal pain
- Increased Hemoglobin
- Hypertension
- nausea
- Anemia
- Breast Tenderness
- rash
- hot flashes
- cough
- gynecomastia
- pruritis
Key clinical trials
- Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas (EARLY_PHASE1)
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer (PHASE2)
- Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. (PHASE2)
- Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex (PHASE1)
- RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (PHASE2)
- Oral Calcitriol With Ketoconazole in CRPC (PHASE2)
- Bioavailability of Levoketoconazole and Ketoconazole Tablets (PHASE1)
- A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketoconazole 200 mg CI brief — competitive landscape report
- Ketoconazole 200 mg updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI